Quadrivalent human papillomavirus (HPV) vaccination was associated with a substantial reduction in the incidence of cervical cancer in a Swedish review of more than 1 million girls and women vaccinated from 2006–2017.

NHS England is warning that the misconception that lesbian, gay and bisexual (LGB) women are not at risk of cervical cancer is putting 50,000 LGB women at risk.

The ‘fake news’ has created a dangerous screening gap, as the affected women have never been for a cervical cancer screening test because they wrongly think they are not at risk.

Continue to Article

As Rwanda gears up for a new round of vaccinations later this year, the immunologist responsible for the vaccine that has saved so many women’s lives believes the world cannot be complacent. “You can’t be happy until everyone has been vaccinated,” Frazer says.

One in every 100 women in Europe will develop cervical cancer.

If diagnosed early, this can be treated. Undiagnosed, it spreads into other parts of the body - leading ultimately to death.

Yet life-saving cervical cancer screening is today at an all-time low, with many women skipping so-called ‘PAP smears’ to avoid potential discomfort at the doctors.

A proposal to simplify cervical cancer screening could end up missing some cancers, researchers and patient advocates say. And that could be especially true for minority women.

Scientists have found that some types of cancers have more of a sweet tooth than others.

Unlike many gynecologic cancers, there is a vaccination and screening test for cervical cancer, an important distinction in preventing and identifying the disease, according to Ursula Matulonis, MD, medical director of Gynecologic Oncology in Dana-Farber’s Susan F. Smith Center for Women’s Cancers, and Colleen Feltmate, MD, director of minimally invasive surgery in Gynecologic Oncology at Brigham and Women’s Hospital.

The death rate from cervical cancer in the United States is considerably higher than previously estimated and the disparity in death rates between black women and white women is significantly wider, according to a study published Monday in the journal Cancer.

Despite the declining incidence of cervical cancer as a result of the introduction of screening programs, globally it remains a leading cause of cancer-related death in women. Outcomes for patients who are diagnosed with anything but early-stage disease remain poor.

But just because this gynecologic cancer occurs less frequently doesn’t mean it’s less deadly.  In fact, cervical cancer was once the No. 1 leading cause of cancer death for women in the US. What’s worse? The disease is almost 100 percent preventable. This fact is especially chilling for Latinas, who have the highest incidence of cervical cancer and the second-highest death rate from the disease.

Half of young women are unable to properly label a vagina on a medical diagram, while 65 per cent have admitted they have a problem simply using the words vagina or vulva.

Avastin works by interfering with the blood vessels that fuel the development of cancerous cells. The new indication for cervical cancer is approved for use in combination with chemotherapy drugs paclitaxel and cisplatin or in combination with paclitaxel and topotecan.

A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type’s molecular idiosyncrasies.........
.....The research was supported by grants from the American Cancer Society, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Team Maureen Cervical Cancer Fund, and the Friends of Dana-Farber Cancer Institute.

Dr. Thomas Schuch was awarded the HPV Vaccine is Cancer Prevention Champion Award by the Center for Disease Control and Prevention (CDC), American Cancer Society (ACS), and the Association of American Cancer Institutes (AACI). The award recognizes clinicians, clinics, practices, groups, and health systems that go above and beyond to encourage HPV vaccination in their communities.

Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.

A new study from The Ohio State University found that mailing at-home HPV tests to hard-to-reach women may be a viable approach, one that could be especially helpful in regions such as Appalachia, where access to women’s health care can be limited.

Pilot study found 80 percent of participants used the tests A new study from The Ohio State University found that mailing at-home HPV tests to hard-to-reach women may be a viable approach, one that could be especially helpful in regions such as Appalachia, where access to women’s health care can be limited.

Question  What are the prevalence of both genital human papillomavirus (HPV) infection and the HPV vaccination rate among adult men in the United States?

Meaning  Male HPV vaccination may have a greater effect on HPV transmission and cancer prevention in men and women than previously estimated.

The largest review of the available evidence on the quadrivalent, or four-strain, HPV vaccine Gardasil, has found no evidence of any serious short-term or long-term safety issues. Bringing together the findings from clinical trials, post-licensure studies and data presented at scientific meetings but not yet published, the researchers focused particularly on autoimmune diseases, nervous system disorders, anaphylaxis, blood clots and stroke – but none of them is caused by the vaccine, they found.

Many American college students don't get vaccinated against human papillomavirus (HPV), and many don't fully understand the threat posed by the virus or their risk for infection, new findings suggest.

Receiving the human papillomavirus vaccine does not increase rates of sexually transmitted infections (STIs) in adolescent females. The vaccine, which can prevent cervical cancer in women, has had a low uptake, partly because of concerns about how it will affect adolescent sexual activity.

About 79 million Americans are currently infected with human papillomavirus, a commonly overlooked sexually transmitted infection, with an estimated 14 million more infected each year, according to the Centers for Disease Control and Prevention. Inevitably, these numbers beg the clinical question: How can HPV be prevented?

A drug called cidofovir that’s already used to target viruses could also be used as part of a novel way to treat cervical cancer

According to a new study published in the Journal of Clinical Virology, researchers have found that there is a strong association between lung tissue with human papillomavirus (HPV) infection, particularly HPV subtypes 16 and 18, and lung cancer.

According to a new study published in the Journal of the American Medical Association, researchers at the Johns Hopkins Boomberg School of Public Health in Baltimore, Maryland, have found that cigarette smokers are more likely to be positive for human papillomavirus (HPV)-16 compared with non-smokers.

A simple urine test can routinely spot human papillomavirus (HPV), according to research published in The BMJ.

Narrated by Vanessa Williams. The Human Papilloma Virus HPV may be the most widespread, misunderstood and potentially dangerous epidemic that most people hardly know anything about. 80 percent of all people under 50 years of age will have a strain of the virus at some point in their lives and most will not even realize they have it. Cervical cancer is almost exclusively caused by HPV and it is the 2nd leading cancer in women. Worldwide, cervical cancer kills over 250,000 women every year. Meet five unforgettable women whose lives have been changed forever and even interrupted by this deadly virus.

In a typical year in the United States about 150 people die from meningococcus, four from tetanus, none from diphtheria, 20 from pertussis, and roughly 4,000 from cancers caused by HPV. People are more than 20 times more likely to die from HPV than from the other four diseases combined.

A comprehensive new study spanning 20 years and 57 vaccines finds vaccines are "remarkably safe" — safer, in fact, than "almost any other modern medical intervention," lead author Dr. Daniel Shepshelovich told Business Insider.

For the study, he and other researchers at Tel Aviv Sourasky Medical Center looked at the labels, including safety-related changes, of 57 vaccines that became FDA-approved between the beginning of 1996 and end of 2015.

Taking a Shot at HPV Prevention!

Young fans who attend the Falmouth High girls’ basketball game on Jan. 31 and the Mashpee High boys’ basketball game on Feb. 14 will have the opportunity to spin a prize wheel and participate in a halftime basketball free-throw contest.

At the 3^rd Annual “Take the Shot Night,” they will also, along with their parents/guardians, learn about a different shot that will protect them from the HPV virus and HPV-related cancers.

A new meta-analysis published in The Lancet in June shows the HPV vaccine is very effective and is expected to lower the rate of cervical and other related cancers.

The researchers reviewed data from 60 million young men and women in 14 high-income nations, with up to 8 years of post-vaccination follow-up. Continue to the Cape Cod Health News Article.

‘Is Gardasil 9 right for me?” my patient asked during a recent office visit.

She is 45, recently divorced from her husband of 20 years and crafting her online dating profile. She’s also wondering whether she is a candidate for the vaccine that protects against nine strains of the human papilloma virus (HPV) — a virus that causes most cervical, oral and anal cancer.

Jason Mendelsohn was pondering a question during a financial exam in 2014 when his fingers grazed his neck, making him notice a bump he hadn’t felt before.

He consulted his father, a doctor, who told him they’d need to call an ear, nose and throat physician. This led to a doctor’s consultation, which eventually led to a diagnosis. At 44, he was told he had HPV-related throat cancer.

CDC today recommended that 11- to 12-year-olds receive two doses of HPV vaccine at least six months apart rather than the previously recommended three doses to protect against cancers caused by human papillomavirus (HPV) infections. Teens and young adults who start the series later, at ages 15 through 26 years, will continue to need three doses of HPV vaccine to protect against cancer-causing HPV infection.

A vaccine introduced a decade ago to combat the sexually transmitted virus that causes cervical cancer has already reduced the virus’s prevalence in teenage girls by almost two-thirds, federal researchers said Monday.

Merck announced that the Food and Drug Administration (FDA) has expanded the age indication for Gardasil 9 (human papillomavirus 9-valent vaccine [recombinant]) in males. It now includes use in males aged 16–26 for the prevention of anal cancer caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 59; precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and genital warts caused by HPV types 6 and 11.

More adolescents received the HPV vaccine when the vaccine was discussed in the context of other vaccines, and when the providers said they expected that the vaccine would be administered at the visit, results from a multisite study suggest.

Vaccines against human papillomavirus (HPV) are recommended for routine use in adolescents aged 11 to 12 years in the United States, but uptake remains suboptimal. Educational interventions focused on parents and patients to increase coverage have not generally demonstrated effectiveness.

The goal of this study was to identify the rationale by parents/guardians and providers for delaying or administering human papillomavirus (HPV) vaccination to girls.

"When administered to adolescents, the HPV4 vaccine demonstrated durability in clinically effective protection and sustained antibody titers over eight years," concluded the researchers.

A new study from the Karolinska Institutet in Sweden found no association between the human papillomavirus (HPV) vaccine and short- or long-term health concerns.

Researchers have advanced a cancer vaccine to human trials as part of pioneering research aimed at treating incurable HPV cancers of the head, neck, throat and tongue.

The research combines a newly developed Human Papillomavirus (HPV) vaccine with immunotherapy and is being spearheaded by Professor Ian Frazer and Brisbane's Princess Alexandra Hospital's Professor Sandro Porceddu.

"We are seeing an unprecedented rise in the incidence of HPV-associated oropharyngeal cancer (OPC) with the USA reporting a 225 per cent increase since the 1980s," Professor Porceddu said.